Controlled ‘Europeanisation’? The KMW–Nexter merger and the Germany’s new strategy for the arms industry. OSW COMMENTARY NUMBER 180/26.08.2015

On 29 July a deal was signed in Paris concerning a merger between Krauss-Maffei Wegmann (KMW), Germany’s largest manufacturer of tanks, infantry fighting vehicles and artillery systems, and its French counterpart Nexter. The new holding formed as a result of the merger will be Europe’s largest producer of arms systems for land forces, comparable to the Airbus Group in the aerospace industry. While work on finalising the merger was underway, the German government was developing a new strategy for Germany’s arms industry, which was published on 9 June 2015. The strategy’s provisions show that German politicians, despite holding negative opinions on previous mergers between German arms companies and foreign businesses, have concluded that consolidation at the European level is nonetheless the only way to go. However, the strategy also states that the German government should exercise more influence than previously on the terms and conditions of any such consolidation. To this end, it identified key national technologies which will be supported and protected through various instruments, including also the conclusion of intergovernmental agreements on strategic defence co-operation. Such agreements may regulate questions such as the ownership structures of the new companies, the locations for developing technologies and for manufacturing products, subcontractors and exports of jointly developed arms and military equipment. In relation to the KMW–Nexter merger, such a deal between France and Germany is expected to be signed this autumn.

Facing the fourth foreign fighters wave. What drives Europeans to Syria, and to Islamic state? Insights from the Belgian case. Egmont Paper 81, March 2016

‘A bizarre phenomenon,’ Der Spiegel concluded, after trying to figure out why young people left Germany to become foreign fighters in Syria. The magazine painted a portrait of two thirty-somethings with similar backgrounds and the same hobby – martial arts. One became director of a martial arts school in Hamburg, the other became a terrorist poster boy in Syria.2

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.

BACKGROUND The monoclonal antibody natalizumab (NAT) inhibits the migration of lymphocytes throughout the blood-brain barrier by blocking very late antigen (VLA)-4 interactions, thereby reducing inflammatory central nervous system (CNS) activity in patients with multiple sclerosis (MS). We evaluated the effects of different NAT treatment regimens. METHODS We developed and optimised a NAT assay to measure free NAT, cell-bound NAT and VLA-4 expression levels in blood and cerebrospinal fluid (CSF) of patients using standard and prolonged treatment intervals and after the cessation of therapy. RESULTS In paired CSF and blood samples of NAT-treated MS patients, NAT concentrations in CSF were approximately 100-fold lower than those in serum. Cell-bound NAT and mean VLA-4 expression levels in CSF were comparable with those in blood. After the cessation of therapy, the kinetics of free NAT, cell-bound NAT and VLA-4 expression levels differed. Prolonged intervals greater than 4 weeks between infusions caused a gradual reduction of free and cell-bound NAT concentrations. Sera from patients with and without NAT-neutralising antibodies could be identified in a blinded assessment. The NAT-neutralising antibodies removed NAT from the cell surface in vivo and in vitro. Intercellular NAT exchange was detected in vitro. CONCLUSIONS Incorporating assays to measure free and cell-bound NAT into clinical practice can help to determine the optimal individual NAT dosing regimen for patients with MS.

Economic impact of effluent regulations on the rum industry, Puerto Rico and U.S. Virgin Islands /

Study conducted by Development, Planning and Research Associates, Inc.

Cancer in the rubber industry : the risks and what you can do about them.

"OSHA 3068"--Cover.

Nuclear power industry : joint hearing before the Committee on Energy and Natural Resources and the Subcommittee on Energy and Water Development of the Committee on Appropriations, United States Senate, One Hundred Seventh Congress, first session to conduct oversight on the state of the nuclear power industry and the future of the industry in a comprehensive energy strategy, May 3, 2001.

Shipping list no.: 2001-0300-P.

The insurance industry. Hearings before the Subcommittee on Antitrust and Monopoly of the Committee on the Judiciary, United States Senate, Eighty-fifth Congress, second session, pursuant to S. Res. 231 ...

Continuous paging.

The United States and world trade--its challenges and opportunities : Address of the Honorable Rowland Burnstan, Assistant Secretary of Commerce for international affairs, at luncheon meeting of International trade club of Chicago, La Salle Hotel, Chicago, Illinois, June 15, 1961.

Reproduced from typewritten copy.